UNSPSC 51322203: Rosuvastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C22H28FN3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 413KH5ZJ73, chemically known as (3r,5s,6e)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid but generally known as rosuvastatin, which bears US NIH Compound Identifier 446157. European Medicines Agency schedules Rosuvastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20634.

UNSPSC 51322203 Rosuvastatin is a Commodity code for a single pharmaceutical product, but state and local procurement activity under this code does not align with the medication being procured. The City of Tampa's recent solicitation (Bid No. 26-P-00188, posted April 24, 2026) tagged under this code actually seeks Advanced Life Support Medications — Labetalol HCI, Epinephrine, Adenosine, and Diltiazem — for Tampa Fire Rescue. These are emergency cardiac and acute-care drugs, not rosuvastatin (a statin used for cholesterol management). The mismatch suggests the code classification may be a data error or that the UNSPSC taxonomy is being applied inconsistently in this jurisdiction's procurement system. State and local procurement under UNSPSC 51322203 shows little relevant recent activity aligned with the code's nominal scope.

The Tampa opportunity is an IFB for pharmaceuticals to stock emergency response vehicles, with an estimated contract value of $40,000.00 and a response deadline of April 8, 2026. The City requires nine-month minimum shelf life, ten-day delivery, and a one-year initial term with two optional renewals plus unilateral extension rights for three 30-day periods. The solicitation includes a 5 percent Small Local Business Enterprise (SLBE) bid discount (capped at $10,000.00) and mandates OSHA-compliant Safety Data Sheets and WCAG 2.2 Level AA accessibility documentation. Award will be made to the lowest responsive, responsible bidder within 120 days of bid opening. This is the only recent opportunity identified under the code, and it does not substantively reflect rosuvastatin procurement.